Coronavirus Update: iSPOCs, Fake Drugs & Data Protection Concerns
Executive Summary
In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers events at EU and member state level, as well as initiatives by international regulators.
You may also be interested in...
If Drug Distributors Can Coordinate Without Anti-Trust Concerns During The Coronavirus Pandemic, What About Generic Manufacturers?
Experts and stakeholders suggest it may help avoid drug shortages, but also indicate the interaction, which in normal times would raise anti-trust concerns, may not be needed, even to fight coronavirus.
EU Launches Fast-Track Monitoring Of Crucial COVID-19 Drug Shortages
A new system for monitoring the availability of medicines for treating COVID-19 patients will allow EU-level coordinated actions to address supply shortages in the best way.
COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs and Tests
Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.